Novel fat depot-specific mechanisms underlie resistance to visceral obesity and inflammation in 11β-hydroxysteroid dehydrogenase type 1-deficient mice

Diabetes

Volumn 60, Issue 4, 2011, Pages 1158-1167

  Wamil, Malgorzata ^a   Battle, Jenny H ^a,b   Turban, Sophie ^b   Kipari, Tiina ^a   Seguret, David ^b   De Sousa Peixoto, Ricardo ^a   Nelson, Yvonne B ^b   Nowakowska, Dominika ^a,b   Ferenbach, David ^a   Ramage, Lynne ^b   Chapman, Karen E ^a   Hughes, Jeremy ^a   Dunbar, Donald R ^a   Seckl, Jonathan R ^a   Morton, Nicholas M ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; ADENOSINE PHOSPHATE; BETA ADRENERGIC RECEPTOR; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRAL INSULIN;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CELL SIZE; CYTOKINE RELEASE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GLUCOSE METABOLISM; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU HYBRIDIZATION; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; LIPID METABOLISM; LIPID STORAGE; MACROPHAGE; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUBCUTANEOUS FAT; T LYMPHOCYTE; WESTERN BLOTTING;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BLOTTING, WESTERN; DIETARY FATS; ENZYME ACTIVATION; FLOW CYTOMETRY; GLUCOCORTICOIDS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; MALE; MICE; MICE, MUTANT STRAINS; OBESITY, ABDOMINAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79953188346     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db10-0830     Document Type: Article

References (53)

1. Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002;51:2951-2958
2. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738 (Pubitemid 32113289)
3. Jensen MD. Role of body fat distribution and the metabolic complications of obesity. J Clin Endocrinol Metab 2008;93(Suppl. 1):S57-S63
4. Tomlinson JW, Stewart PM. Mechanisms of disease: selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 2005;1:92-99
5. Morton NM, Seckl JR. 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front Horm Res 2008;36:146-164
6. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170 (Pubitemid 33150673)
7. Masuzaki H, Yamamoto H, Kenyon CJ, et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 2003;112:83-90 (Pubitemid 38056379)
8. Kershaw EE, Morton NM, Dhillon H, Ramage L, Seckl JR, Flier JS. Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 2005;54:1023-1031 (Pubitemid 40446315)
9. Morton NM, Paterson JM, Masuzaki H, et al. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004;53:931-938 (Pubitemid 38436604)
10. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867 (Pubitemid 46024993)
11. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783 (Pubitemid 44453463)
12. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk-beta. Science 2001;293:1673-1677 (Pubitemid 32807849)
13. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336 (Pubitemid 35398190)
14. Odegaard JI, Chawla A. Mechanisms of macrophage activation in obesity-induced insulin resistance. Nat Clin Pract Endocrinol Metab 2008;4:619-626
15. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808 (Pubitemid 38063703)
16. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821-1830 (Pubitemid 38063705)
17. Wu H, Ghosh S, Perrard XD, et al. T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 2007;115:1029-1038 (Pubitemid 46328297)
18. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007;282:35279-35292 (Pubitemid 350232441)
19. Rausch ME, Weisberg S, Vardhana P, Tortoriello DV. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. Int J Obes (Lond) 2008;32:451-463 (Pubitemid 351414814)
20. Gudbjornsson B, Juliusson UI, Gudjonsson FV. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann Rheum Dis 2002;61:32-36 (Pubitemid 34074836)
21. Reichardt HM, Schütz G. Glucocorticoid signalling - multiple variations of a common theme. Mol Cell Endocrinol 1998;146:1-6 (Pubitemid 29003274)
22. Stimson RH, Andersson J, Andrew R, et al. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans. Diabetes 2009;58:46-53
23. Martinez FO, Gordon S, Locati M, Mantovani A. Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol 2006;177:7303-7311 (Pubitemid 44715100)
24. Gilmour JS, Coutinho AE, Cailhier JF, et al. Local amplification of glucocorticoids by 11 beta-hydroxysteroid dehydrogenase type 1 promotes macrophage phagocytosis of apoptotic leukocytes. J Immunol 2006;176:7605-7611 (Pubitemid 43853055)
25. Coutinho AE, Gray M, Sawatzky DA, et al. Deficiency in 11β-hydroxysteroid dehydrogenase type 1 results in a more rapid and severe inflammation. American Endocrine Society Abstract 2008:2-8
26. Heasman SJ, Giles KM, Ward C, Rossi AG, Haslett C, Dransfield I. Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol 2003;178:29-36 (Pubitemid 36927006)
27. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008;84:644-650
28. Zhang TY, Daynes RA. Macrophages from 11beta-hydroxysteroid dehydrogenase type 1-deficient mice exhibit an increased sensitivity to lipopolysaccharide stimulation due to TGF-beta-mediated up-regulation of SHIP1 expression. J Immunol 2007;179:6325-6335
29. Hughes KA, Webster SP, Walker BR. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert Opin Investig Drugs 2008;17:481-496 (Pubitemid 351578167)
30. De Sousa Peixoto RA, Turban S, Battle JH, Chapman KE, Seckl JR, Morton NM. Preadipocyte 11beta-hydroxysteroid dehydrogenase type 1 is a keto-reductase and contributes to diet-induced visceral obesity in vivo. Endocrinology 2008;149:1861-1868 (Pubitemid 351468317)
31. Beauloye V, Ketelslegers JM, Moreau B, Thissen JP. Dexamethasone inhibits both growth hormone (GH)-induction of insulin-like growth factor-I (IGF-I) mRNA and GH receptor (GHR) mRNA levels in rat primary cultured hepatocytes. Growth Horm IGF Res 1999;9:205-211 (Pubitemid 29468753)
32. Berthiaume M, Laplante M, Festuccia W, et al. Depot-specific modulation of rat intraabdominal adipose tissue lipid metabolism by pharmacological inhibition of 11beta-hydroxysteroid dehydrogenase type 1. Endocrinology 2007;148:2391-2397 (Pubitemid 46997032)
33. Fan GC, Chu G, Mitton B, Song Q, Yuan Q, Kranias EG. Small heat-shock protein Hsp20 phosphorylation inhibits beta-agonist-induced cardiac apoptosis. Circ Res 2004;94:1474-1482 (Pubitemid 38780320)
34. Himms-Hagen J, Melnyk A, Zingaretti MC, Ceresi E, Barbatelli G, Cinti S. Multilocular fat cells in WAT of CL-316243-treated rats derive directly from white adipocytes. Am J Physiol Cell Physiol 2000;279:C670-C681
35. Granneman JG, Li P, Zhu Z, Lu Y. Metabolic and cellular plasticity in white adipose tissue I: effects of beta3-adrenergic receptor activation. Am J Physiol Endocrinol Metab 2005;289:E608-E616 (Pubitemid 41356082)
36. Kim CS, Lee SC, Kim YM, et al. Visceral fat accumulation induced by a high-fat diet causes the atrophy of mesenteric lymph nodes in obese mice. Obesity (Silver Spring) 2008;16:1261-1269 (Pubitemid 351770531)
37. Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev 2002;18(Suppl. 2):S10-S15 (Pubitemid 34467309)
38. Ngo S, Barry JB, Nisbet JC, Prins JB, Whitehead JP. Reduced phosphorylation of AS160 contributes to glucocorticoid-mediated inhibition of glucose uptake in human and murine adipocytes. Mol Cell Endocrinol 2009;302:33-40
39. de Souza CJ, Hirshman MF, Horton ES. CL-316,243, a beta3-specific adrenoceptor agonist, enhances insulin-stimulated glucose disposal in nonobese rats. Diabetes 1997;46:1257-1263
40. Soumano K, Desbiens S, Rabelo R, Bakopanos E, Camirand A, Silva JE. Glucocorticoids inhibit the transcriptional response of the uncoupling protein-1 gene to adrenergic stimulation in a brown adipose cell line. Mol Cell Endocrinol 2000;165:7-15 (Pubitemid 30625178)
41. Festuccia WT, Oztezcan S, Laplante M, et al. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 2008;149:2121-2130 (Pubitemid 351574485)
42. Carter RN, Paterson JM, Tworowska U, et al. Hypothalamic-pituitary- adrenal axis abnormalities in response to deletion of 11beta-HSD1 is strain-dependent. J Neuroendocrinol 2009;21:879-887
43. LeBrasseur NK, Kelly M, Tsao TS, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-E181 (Pubitemid 44035323)
44. Hattori A, Mawatari K, Tsuzuki S, et al. Beta-adrenergic-AMPK pathway phosphorylates acetyl-CoA carboxylase in a high-epinephrine rat model, SPORTS. Obesity (Silver Spring) 2010;18:48-54
45. Christ-Crain M, Kola B, Lolli F, et al. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome. FASEB J 2008;22:1672-1683 (Pubitemid 351811445)
46. Berggreen C, Gormand A, Omar B, Degerman E, Göransson O. Protein kinase B activity is required for the effects of insulin on lipid metabolism in adipocytes. Am J Physiol Endocrinol Metab 2009;296:E635-E646
47. Kelly IE, Han TS, Walsh K, Lean ME. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-293 (Pubitemid 29056924)
48. Yamauchi T, Kamon J, Waki H, et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR-gamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001;276:41245-41254
49. Hoene M, Weigert C. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev 2008;9:20-29 (Pubitemid 350264626)
50. Ruderman NB, Keller C, Richard AM, et al. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 2006;55 (Suppl. 2):S48-S54
51. Hoppmann J, Perwitz N, Meier B, et al. The balance between gluco- and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 2010;204:153-164
52. Hermanowski-Vosatka A, Balkovec JM, Cheng K, et al. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 2005;202:517-527 (Pubitemid 41186950)
53. Kanda H, Tateya S, Tamori Y, et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 2006;116:1494-1505